Nivo has opened access to Nivo AI, its purpose-built agentic AI assistant for specialist lending, to the wider broker and lender market following a successful earlyNivo has opened access to Nivo AI, its purpose-built agentic AI assistant for specialist lending, to the wider broker and lender market following a successful early

Nivo Rolls Out Nivo AI to Brokers and Lenders Following Successful Early Adopter Phase

2026/03/06 20:33
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Nivo has opened access to Nivo AI, its purpose-built agentic AI assistant for specialist lending, to the wider broker and lender market following a successful early adopter phase.

Designed to improve submission quality and reduce friction across broker-lender workflows, Nivo AI operates 24/7 over email, guiding brokers through applications, identifying missing information, structuring cases correctly and delivering lender-ready submissions designed to be ‘right first time’.

The wider rollout comes as AI adoption accelerates across financial services, with firms increasingly seeking practical, workflow-embedded solutions rather than standalone tools.

Nivo AI was developed to tackle the challenge of incomplete or poorly packaged submissions that create delays, repeated clarification requests and unnecessary strain on underwriting teams. By guiding brokers at source and structuring cases automatically, the platform reduces back-and-forth and improves deal flow quality before cases reach decision-makers.

To support adoption across firms of all sizes, Nivo is launching with a two-week free trial, giving lenders and brokers the opportunity to experience guided packaging, automated document structuring and criteria-aware prompts in live scenarios and with no obligation.

Following the trial, firms can choose between two implementation routes depending on their operational complexity and integration requirements:

– Fully integrated, funded projects for lenders seeking to embed Nivo AI across complex journeys, connecting directly into CRMs, case management systems and underwriting workflows.

– A rapid-start version designed for lenders and brokerages that want to deploy quickly with minimal configuration – immediately reducing email back-and-forth and improving ‘right first time’ submissions from day one.

Nivo’s secure messaging platform has been adopted by more than 100 financial services firms and used by over one million customers since launching in 2017. Today, Nivo AI represents the company’s evolution from secure communication to intelligent deal orchestration embedded directly into specialist lending workflows.

Matthew Elliott, Co-Founder of Nivo, said:

“Specialist lending doesn’t lack demand, but we all know it suffers from friction. During our early adopter phase, we focused on proving that AI could materially improve submission quality and reduce unnecessary back-and-forth between brokers and lenders. The results have been extremely encouraging.

“Nivo AI isn’t a generic chatbot bolted onto a workflow. It’s purpose-built for specialist lending – understanding packaging requirements, document standards and lender criteria. One prompt. The whole deal.”

The post Nivo Rolls Out Nivo AI to Brokers and Lenders Following Successful Early Adopter Phase appeared first on FF News | Fintech Finance.

Market Opportunity
Falcon Finance Logo
Falcon Finance Price(FF)
$0.07562
$0.07562$0.07562
+2.94%
USD
Falcon Finance (FF) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09